<DOC>
	<DOCNO>NCT00025415</DOCNO>
	<brief_summary>Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Phase I trial study effectiveness imatinib mesylate treat patient advanced cancer liver dysfunction</brief_summary>
	<brief_title>Imatinib Mesylate Treating Patients With Advanced Cancer Liver Dysfunction</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose dose-limiting toxicity imatinib mesylate patient advanced malignancy vary degree liver dysfunction . II . Determine effect hepatic dysfunction pharmacodynamics pharmacokinetics drug patient . III . Determine non-dose-limiting toxic effect drug patient . IV . Determine response rate patient treat drug . V. Correlate Childs-Pugh classification hepatic dysfunction observe toxic effect , pharmacodynamics , pharmacokinetics drug patient . OUTLINE : This dose-escalation , multicenter study . Patients stratify accord liver dysfunction ( normal v mild v moderate v severe ) . Patients receive oral imatinib mesylate daily . Courses repeat every 4 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient within stratum ( except normal stratum ) receive escalate dos imatinib mesylate maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 60 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic , Atypical , BCR-ABL Negative</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Leukemia , Neutrophilic , Chronic</mesh_term>
	<mesh_term>Paraproteinemias</mesh_term>
	<mesh_term>Monoclonal Gammopathy Undetermined Significance</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Histologically cytologically confirm surgically incurable solid tumor orhematologic malignancy standard palliative therapy exist oris longer effective All tumor type eligible , include : Chronic myelogenous leukemia Philadelphia chromosomepositive leukemia OR Gastrointestinal stromal tumor Patients gliomas require corticosteroids anticonvulsant must beon stable dose seizurefree 1 month No unstable untreated ( nonirradiated ) brain metastasis Performance status ECOG 02 Performance status Karnofsky 60100 % More 3 month WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 No active hemolysis See Surgery No evidence biliary sepsis Creatinine normal Creatinine clearance least 60 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Able swallow pills No uncontrolled concurrent illness would preclude study participation No ongoing active infection No uncontrolled diarrhea No psychiatric illness social situation would preclude study compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 6 month study completion At least 24 hour since prior colonystimulating factor No concurrent colonystimulating factor At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover See Disease Characteristics See Disease Characteristics At least 4 week since prior radiotherapy recover See Disease Characteristics At least 10 day since prior placement shunt treatment biliary obstruction At least 14 day since prior major surgery No prior solid organ transplantation No concurrent investigational agent No concurrent therapeutic dos warfarin anticoagulation No concurrent investigational commercial agent therapy treatment disease No concurrent combination antiretroviral therapy HIVpositive patient No concurrent acetaminophen 4,000 mg/day</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>